Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925737 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
A Phase 3 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,440
- Enrollment target
- 20
- Study locations
NCT06925737: Recruiting Phase 3 study of Prostate Cancer and Prostatic Neoplasms, sponsored by Merck Sharp & Dohme.
NCT06925737 is a Phase 3 study of Prostate Cancer and Prostatic Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 1,440 participants, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (138% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06925737, a Phase 3 study of Prostate Cancer and Prostatic Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,440 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Primary Outcome
OS is defined as the time from randomization to death due to any cause.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Rescue Medication
- DRUG Prednisone
- DRUG Ifinatamab deruxtecan
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center ( Site 0049) - Duarte
- City of Hope Lennar Foundation Cancer Center ( Site 0059) - Irvine
- Moores Cancer Center ( Site 0010) - La Jolla
- Cedars-Sinai Medical Center ( Site 0068) - Los Angeles
- UCLA Hematology/Oncology - Santa Monica ( Site 0002) - Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006) - Orange
- Stanford Cancer Center ( Site 0046) - Palo Alto
Connecticut
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0050) - New Haven
- Veterans Affairs Connecticut Healthcare System ( Site 0062) - West Haven
District of Columbia
- The GW Medical Faculty Associates ( Site 0057) - Washington D.C.
- Washington DC Veterans Affairs Medical Center ( Site 0056) - Washington D.C.
Georgia
- Emory University School of Medicine- Grady Campus ( Site 0103) - Atlanta
- Winship Cancer Institute, Emory University ( Site 0003) - Atlanta
Arizona
- Mayo Clinic in Arizona - Phoenix ( Site 0044) - Phoenix
Colorado
- Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053) - Aurora
Florida
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077) - Jacksonville
Illinois
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063) - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,440 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2031-01-06 |
| Phase | Phase 3 |
What NCT06925737 shows while recruiting
NCT06925737 is an interventional study that assigns participants to a tested intervention. Its 1,440 participants enrollment target places it among the larger protocols in the corpus, above the 606-participant average among 735 other Prostate Cancer trials with a reported enrollment target (138% higher).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT06925737 names 20 study sites across 11 states, led by California, Connecticut, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06925737 about?
NCT06925737 is a clinical study titled "A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)". Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ove...
What is the current status of trial NCT06925737?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,440 participants. The study started on 2025-05-13. Estimated completion is 2031-01-06.
What conditions does trial NCT06925737 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms.
What interventions are being tested in trial NCT06925737?
The interventions under investigation include: Docetaxel (DRUG), Rescue Medication (DRUG), Prednisone (DRUG), Ifinatamab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06925737?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925737 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06925737's enrollment target sits among peer trials
1,440 39th of 735 higher than 697 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI